Developments in the field of biotechnology have been categorized into three ‘waves’ or stages. In the first stage or the ‘green wave’, the industry was dominated by the agricultural applications of biotechnology. This was followed by medical applicat ....see more
The NGS sample preparation market is projected to grow from USD 1.1 billion in 2019 to USD 2.7 billion by 2024, at a CAGR of 18.7% during the forecast period. Factors such as advancements in NGS platforms, reduced cost of sequencing, and improving reimbursement scenario for NGS-based diagnostic tests are driving the growth of this market. However, while the costs involved in NGS have reduced to some extent, they have not reached a level where broad adoption across developing markets can be achieved. This is a key restraint for market growth.Illumina Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Beckman Coulter (a subsidiary of Danaher), Becton, Dickinson and Company (BD) (US), and Pacific Biosciences of California (US).
The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.
The reporter gene assays market is projected to reach USD 2.6 billion by 2024 from USD 1.6 billion in 2019, at a CAGR of 10.1%. Factors contributing to the growth of this market include increasing funding for cell-based research, growing applications of gene expression, and rising preference for cell-based assays. The prominent players in the reporter gene assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Danaher Corporation (US), Geno Technology (US), Genecopoeia, Inc. (US), InvivoGen (France), PromoCell (Germany), Becton, Dickinson and Company (US), Biotium, Inc. (US), Canvax (Spain), LI-COR, Inc. (US), System Biosciences, LLC (US), Indigo Biosciences, Inc. (US), BioThema (Sweden), Takara Bio Inc (US), BioAssay Systems (US), Cell Biolabs, Inc. (US), BPS Bioscience, Inc (US), Biosynth AG (Switzerland), and Cayman Chemical (US).
The miRNA sequencing and assays market is projected to reach USD 343 million by 2024 from USD 182 million in 2018, at a CAGR of 11.2%. Growth in this market is driven by factors such as the advantages of miRNA sequencing over other technologies, increasing research funding for genomics, and the decreasing cost of sequencing.Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Germany), Takara Bio (Japan), NEB (UK), and 5 others.
The market for immunoprecipitation is expected to grow from USD 560 million in 2018 to USD 750 million by 2024, at a CAGR of 5.0% during the forecast period. The growth of this market is majorly driven by the increasing research in the life sciences industry and the growing need to identify antigens associated with autoimmune diseases (through antigen-antibody interaction to understand disease mechanisms and develop relevant drugs targeting these diseases). The prominent players in the global immunoprecipitation market are Thermo Fisher Scientific (US), Abcam (UK), and Merck KGaA (Germany)
The market for filter integrity test is projected to reach USD 79 million by 2024 from USD 59 million in 2018, at a CAGR of 5.0% during the forecast period. Factors such as increasing R&D spending, growth in the biopharmaceutical industry, and increasing purity requirements in the end-user market are driving the growth of the filter integrity test market. The major players in the filter integrity test market are Merck KGaA (Germany), Danaher Corporation/Pall Corporation (US), Sartorius (Germany), Donaldson Company (US), Parker Hannifin Corporation (US), Meissner Filtration Product (US), MDI Filtration Technologies (US), Thermo Fisher Scientific (US), Eaton Corporation (Ireland), and SH-Surway (China).
The cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1% during the forecast period. Factors such as the increasing funding for life sciences research, high global prevalence of cancer, and growth in stem cell and neurobiology research are expected to drive the growth of this market in the coming years.
The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Growth in this market can be attributed to factors such as the growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years. The bioburden testing market is competitive in nature, with the presence of several large and small players. Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific (US), biomérieux SA (France), and Pacific BioLabs (US) are some of the leading payers in the bioburden testing market.
The market size for synthetic stem cells is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period. The ethical concerns on the use of embryonic stem cells and the risk of tumor formation and immune response to natural stem cells are the key factors driving the growth of this market. The key developers of synthetic stem cell technology are North Carolina State University (NCSU) (US) and Zhengzhou University (China).
The gel documentation systems market is projected to grow from USD 258 million in 2018 to USD 304 million by 2023, at a CAGR of 3.3% during the forecast period. Growth in the gel documentation systems market is mainly driven by the increasing prevalence of infectious and chronic disease, and rising research & development expenditure in the pharmaceutical and biotechnology companies. The major players in the gel documentation systems market are GE Healthcare (US), Bio-Rad Laboratories, inc. (US), Thermo Fisher Scientific (US), LI-COR Biosciences (US), Endress+Hauser Management AG (Switzerland), Vilber Lourmat (France), Scientific Digital Imaging plc (UK), Bio-Techne (US), Cleaver Scientific (US), and Azure Biosystems (US).
The global genotyping assay market is projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a CAGR of 22.0%. The growth of this market is mainly driven by technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases. The prominent players in the genotyping market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).
The protein sequencing market is projected to grow from an estimated USD 925 million in 2018 to USD 1,088 million by 2023, at a CAGR of 3.3% during the forecast period. Growth in the protein sequencing market is mainly driven by the increasing focus on target-based drug development by pharmaceutical and biotechnology companies, advancements in clinical Mass Spectrometry and analytical techniques, and increasing public-private financial support for proteomic research. Some of the prominent players in the protein sequencing market include Shimadzu (Japan), Thermo Fisher Scientific Inc. (US), SGS S.A. (Switzerland), Waters Corporation (US), Rapid Novor (Canada), Agilent Technologies (US), Charles River Laboratories (US) and Selvita (Poland).
The market for CRISPR technology is expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period. The rise in the availability of government and private funding and the adoption of CRISPR technology are the key factors driving the growth of this market. Some of the key players of CRISPR in this region are Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).
The global apoptosis assays market is projected to reach USD 5.9 billion by 2023 from USD 3.6 billion in 2018, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).
The market for gene expression analysis market is expected to grow from USD 3.2 billion in 2018 to USD 4.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 8.8% during the forecast period. The major players operating in the gene expression analysis market include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are the key players in the gene expression analysis market. Other players involved in this market are F. Hoffmann-La Roche Ltd. (Switzerland), GE Healthcare (UK), Pacific Biosciences of California, Inc. (US), BGI (China), PerkinElmer (US), Agilent Technologies Inc. (US), and QIAGEN N. V. (Netherlands), among others.
The global desalting and buffer exchange market is projected to reach USD 1,094.8 million by 2023 from USD 679.8 million in 2018, at a CAGR of 10.0%. The base year considered for the study is 2017, and the market forecast is provided for 2018–2023. Growth in this market will largely be driven by increasing demand for mAbs, increasing R&D expenditure by pharmaceutical and biopharmaceutical companies, and growing focus on proteomic and genomic research. Key players in the global desalting and buffer exchange market are Thermo Fisher Scientific (US), Merck (US), GE Healthcare (US), Danaher (US), and Sartorius (Germany).
The global viral clearance market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period. The growth of this market is primarily driven by factors such as the growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and high incidence and large economic burden of chronic diseases. The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%. Factors contributing to the growth of this market include the rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics. The prominent players in the cell viability assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).
The track etched membrane market is expected to reach USD 813.1 million by 2023 from USD 476.0 million in 2018, at a CAGR of 11.3% from 2018 to 2023. Key factors driving the growth of this market include increasing R&D spending in the pharmaceutical and biopharmaceutical industries and increasing purity requirements among end users of track etched membranes. However, the high cost of production and the limited supply of track etched Membranes are major factors that are expected to restrain the growth of this market during the forecast period. Key players operating in the global track etched membrane are GE Healthcare (US), Danaher (US), Corning (US), Merck (Germany), it4ip (Belgium), Sterlitech (US), Oxyphen (Switzerland), Sarstedt (US), BRAND GMBH (Germany), Sartorius (Germany), SABEU (Germany), Zefon International (US), GVS (Italy), Thermo Fisher Scientific (US), Eaton (Ireland), Greiner Bio-One (Austria), MACHEREY-NAGEL (Germany), Avanti Lipids Polar (US), SKC (US), Advantec (Canada), Avestin (Canada), Scaffdex (Finland), and Graver Technologies (US).
The global hydrophobic interaction chromatography market is projected to reach USD 418.2 million in 2023 from USD 271.0 million in 2017, at a CAGR of 7.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. In the current market scenario, there is a growing demand for hydrophobic interaction chromatography. The major factors driving the growth of this market are the increasing demand for monoclonal antibodies and increasing R&D expenditure in biopharmaceuticals. The key players in the global hydrophobic interaction chromatography market are GE Healthcare (US), Bio-Rad Laboratories (US), Sartorius (Germany), and Thermo Fisher Scientific (US).
The major players operating in the global protein binding assay market are Thermo Fisher (US), HTDialysis (US), Merck (US), GE Healthcare (US), and Absorption Systems (US). The global protein binding market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at a CAGR of 10.7%. The growing number of drug discovery activities, the minimizing drug discovery and development costs, and the increase in pharmaceutical R&D expenditure are driving the growth of this market. The key players in the global protein binding assays market are HTDialysis (US), Thermo Fisher Scientific (US), Merck (Germany), and Sovicell (Germany).
The global microarray analysis market is expected to reach USD 5.52 billion by 2023 from USD 3.82 billion in 2018, at a CAGR of 7.6%. The major factors driving the growth of this market are the increasing incidence of cancer, increasing funding for genomic and proteomic research, and growing application areas of microarrays. Key players in the microarray analysis market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Molecular Devices (US), PerkinElmer Inc. (US), Illumina, Inc. (US), GE Healthcare (US), and Bio-Rad Laboratories Inc. (US).
The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0%. Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the viral vector manufacturing market. The major players in the global viral vector manufacturing market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Kaneka Eurogentec (Japan), and Spark Therapeutics (US).
The global transfer membrane market is expected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period. Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of transfer membrane market. The key players in the transfer membrane market include Merck KGaA (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Pall Coporation (US), Advansta (US), GVS (Italy), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India), among others.
The global creatinine measurement market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%. The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives. The creatinine measurement market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include F. Hoffmann-la Roche Ltd (Switzerland)., Abbott Laboratories (US), Danaher Corporation (US), Thermo Fisher Scientific Inc (US), Siemens Healthineers (Germany), Randox Laboratories (UK)., Pointe Scientific, Inc (US), Sentinel Ch. Spa. (Italy), Diasys Diagnostic Systems GmbH (Germany), Dialab GmbH (Vienna), Diazyme Laboratories, Inc (US), Wako Pure Chemical Industries, Ltd. (Japan), Ortho Clinical Diagnostics (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
The global gene panel market is expected to reach USD 2.95 Billion by 2023 from USD 1.22 Billion in 2018, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
The global neuroscience antibodies and assays market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. The neuroscience antibodies and assays market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies and assays market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).
The global stem cell banking market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%. Factors such as public awareness related to the therapeutic potential of stem cells; development of novel technologies for stem cell preservation, processing, and storage; rising number of hematopoietic stem cell transplantations (HSCTs); and increasing number of stem cell-based research are driving the growth of the market. As of 2017, major players in the global stem cell banking market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).
The lung in vitro models market is projected to reach USD 427.4 Million by 2023 from USD 190.5 Million in 2018, at a CAGR of 17.5%. The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, advancements in Cell Culture technologies, and the development of new 3D in vitro models. The major players in the Lung in vitro models market include Epithelix (Switzerland), MatTek Corporation (US), Lonza (Switzerland), ATCC (US), InSphero (Switzerland), Emulate (US), AlveoliX (Switzerland), Oncotheis (Switzerland), Insphero (Switzerland), TissUse (Switzerland), Mimetas (Netherlands), and CN Bio Innovations (UK).
The global stem cell assay market is expected to reach USD 1,978.7 Million by 2023 from USD 791.9 Million in 2018, at a CAGR of 20.1%. The market growth is primarily driven by increasing government and private funding for stem cell research and technological innovations in stem cell research-based instruments. Key players in the stem cell assay market include Thermo Fisher Scientific (US), GE Healthcare (US), Merck (Germany), Bio-Rad Laboratories (US), Promega Corporation (US), Agilent Technologies (US), PerkinElmer (US), Miltenyi Biotec (Germany), Cell Biolabs (US), HemoGenix (US), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), and Cellular Dynamics International (US).
The humanized mouse models market is projected to reach USD 128.9 Million by 2022 from USD 80.3 Million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period. The key factors boosting market growth are increasing number of R&D activities in pharmaceutical and biotechnology companies, increasing number of research activities involving humanized models, continuous support in the form of investments and grants from the government and private sectors, and growing demand for personalized medicine. The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).
The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding. The creatinine assay kits market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Crystal Chem (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).
Cell harvesting is the process of harvesting cells from the culture media during upstream and downstream bioprocessing. Cell harvesters are used extensively for the cell harvesting process and are compatible with a wide range of assays. The global cell harvesting market is expected to reach USD 324.5 Million by 2023 from USD 213.8 Million in 2018, at a CAGR of 8.7%. Rising investments in Regenerative Medicine and cell-based research, growth of the biopharmaceutical and biotechnology industry, and increasing incidence of chronic and infectious diseases are the major driving factors for this market. Some of the major players operating in the cell harvesting market are PerkinElmer (US), Brandel (US), TOMTEC (US), Cox Scientific (UK), Connectorate (Switzerland), Scinomix (US), ADSTEC (Japan), and Terumo BCT (a part of Terumo Corporation) (Japan).
The global thyroid function tests market is projected to USD 1.68 Billion by 2022 from an estimated USD 1.26 Billion in 2017, at a CAGR of 5.9% during the forecast period. This growth can be attributed to factors such as increasing incidence of thyroid disorders, increasing awareness about thyroid disorders, increasing prevalence of lifestyle diseases, rising geriatric population, and increasing consumption of alcohol and tobacco. The prominent players in the global thyroid function tests market include Thermo Fisher (US), Abbott (US), Roche (Switzerland), DiaSorin (Italy), Danaher (US), Kronus (US), Merck (Germany), Cortez Diagnostics (US), bioMérieux (France), Qualigen (US), and Autobio Diagnostics (China).
The organs-on-chips market is expected to reach USD 45.6 Million by 2022 from USD 9.6 Million in 2017, at a CAGR of 36.6%. The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and new products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure. The organs-on-chips market is emerging and high growth potential market with the presence of several small players and startups firms. Some of the players in the organs-on-chips market include Emulate (US), CN Bio (UK), TissUse (Germany), Mimetas (Netherlands), InSphero (Switzerland), Ascendance Bio (US), Kirkstall (UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US).
The global epigenetics market is projected to reach USD 1,605.7 Million by 2022 from USD 854.0 Million in 2017, at a CAGR of 13.5% during the forecast period. Market growth can be attributed to the decreasing sequencing costs, increase in research activities, availability of funding for epigenetics research, and rising prevalence of cancer. The global epigenetics market is characterized by a large number of players. The prominent players in this market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).
Human identification is widely used in forensics, paternity testing, disaster victim identification, and anthropology with DNA analysis/profiling being a key tool in this sector. The global human identification market is expected to reach USD 1740.2 Million by 2022 from USD 928.0 Million in 2017, at a CAGR of 13.4%. Technological advancement, government initiatives for forensic programs, and focus of market players on expanding their reach are the major driving factors for this market. Some of the major players operating in the human identification market Thermo Fisher Scientific Inc. (US), Promega Corporation (US), QIAGEN N.V. (Netherlands), Illumina Inc. (US), GE Healthcare (US), and Agilent Technologies Inc. (US).
The global next-generation sequencing (NGS) services market is projected to reach USD 2,748.6 Million by 2022 from USD 1,059.2 Million in 2017; growing at a CAGR of 21.0%. As of 2016, the major NGS services providers in the global NGS services market included BGI (China), Eurofins Scientific SE (Luxembourg), PerkinElmer, Inc. (U.S.), QIAGEN (Germany), Macrogen Inc. (South Korea), GENEWIZ, Inc. (U.S.), Illumina, Inc. (U.S.), Novogene Corporation (China), GATC Biotech AG (Germany), DNA Link, Inc (South Korea), Genotypic Technology Pvt Ltd (India), LGC Limited (U.K.), Wuxi Apptech Co. Ltd. (China), Zymo Research Corp (U.S.), Source BioScience (U.K.), and Personalis, Inc. (U.S.) among others.
The biobanking market is expected to reach USD 2.69 billion by 2022 from USD 1.72 billion in 2016 at a CAGR of 7.8%. The base year for this study is 2016. The equipment segment is estimated to account for the largest share of the biobanking market in 2017. This is primarily attributed to the increasing number of biobanks and rising number of biosamples around the world, due to which the demand for equipment remains high.
The competent cells market is expected to reach USD 2.22 Billion by 2022 from USD 1.37 Billion in 2017, at a CAGR of 10.2% from 2017 to 2022. Key players operating in the competent cells market include Merck KGaA (Germany), Promega Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S), New England Biolabs (U.S.), Takara Bio (Japan), Agilent Technologies (U.S.), Lucigen (Epicenter) (Illumina) (U.S.), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Bioline (U.K.), Zymo Research (U.S.), Beijing TransGen Biotech Co., Ltd. (China), Source BioScience (U.K.), IBA GmBH (Germany), Genewiz (U.S.), BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), GeneScript Corporation (U.S.), Bio-Rad Laboratories (U.S.), Life Technologies (India) Pvt. Ltd., Cell Applications, Inc. (U.S.), Delphi Genetics (Belgium), Scarab Genomics, LLC (U.S.), and Yeastern Biotech Co., Ltd. (Taiwan).
The global cellular health screening market is expected to reach USD 3.42 Billion by 2022 from USD 2.12 Billion in 2017, at a CAGR of 10.0% during the forecast period. The global cellular health screening market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Quest Diagnostics (U.S.), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (U.S.).
The global preimplantation genetic testing market is expected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%. Other prominent players in the market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.
The global microbiome sequencing services market is poised to reach USD 1,424.7 Million by 2021 from USD 538.0 Million in 2016, at a CAGR of 21.5% from 2016 to 2021. In this report, the global microbiome sequencing services market is broadly segmented by technology, application, research type, laboratory type, end user, and region. On the basis of technology, the market is divided into sequencing by synthesis (SBS), sequencing by ligation (SBL), pyrosequencing, sanger sequencing, and other technologies (such as Omic technologies). The sequencing by synthesis segment is expected to grow at the highest CAGR of the market in 2016.
The protein assays market is expected to reach USD 2.41 Billion by 2022 from USD 1.42 Billion in 2017, at a CAGR of 11.1%. The increasing pharmaceutical & biotech R&D expenditure and the favorable government funding scenario for Proteomics research are the major factors that are expected to drive the growth of the protein assays market during the forecast period.
The cell signaling market is projected to reach USD 3.51 Billion by 2022 from USD 2.53 Billion in 2017, at a CAGR of 6.8%. The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.
The global high-resolution melting analysis market is expected to reach USD 302.1 Million by 2021 from USD 259.4 Million in 2016, at a CAGR of 3.1% during the forecast period of 2016 to 2021. Rising prevalence of infectious diseases and genetic disorders; increasing public-private investments, funds, and grants for research on genetic analysis technologies; and advantages of HRM over other genotyping technologies are the major factors driving market growth.
The global high-content screening market is projected to reach USD 909.0 Million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are growth in funding for cellular research, cost containment in pharma R&D, and technological advancements in HCS solutions. The rapid growth in developing countries across APAC is also expected to provide an opportunity for revenue generation in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of the instruments are expected to restrain the market growth.
The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 212.1 Million in 2016, at a CAGR of 14.4% from 2016 to 2021. Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).
The global downstream processing market is projected to reach USD 22.03 Billion by 2021 from USD 10.32 Billion in 2016, at a CAGR of 16.4% from 2016 to 2021. In this report, the global downstream processing market is broadly segmented on the basis of technique, product, application, end user, and region.